111 related articles for article (PubMed ID: 14767513)
1. Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: identification of responders incorporating the age factor.
Munemoto Y; Iida Y; Ohata K; Saito H; Fujisawa K; Kasahara Y; Mitsui T; Asada Y; Miura S
Oncol Rep; 2004 Mar; 11(3):623-35. PubMed ID: 14767513
[TBL] [Abstract][Full Text] [Related]
2. Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: Association between host or tumor factors and survival.
Munemoto Y; Iida Y; Abe J; Saito H; Fujisawa K; Kasahara Y; Mitsui T; Asada Y; Miura S
Int J Oncol; 2002 Feb; 20(2):403-11. PubMed ID: 11788909
[TBL] [Abstract][Full Text] [Related]
3. Preoperative CEA and PPD values as prognostic factors for immunochemotherapy using PSK and 5-FU.
Takahashi Y; Mai M; Nakazato H
Anticancer Res; 2005; 25(2B):1377-84. PubMed ID: 15865094
[TBL] [Abstract][Full Text] [Related]
4. Prognostic markers for immunochemotherapy using tegafur -uracil (UFT) and protein-bound polysaccharide K (PSK).
Yoshinaga K; Saeki H; Oki E; Morita M; Ikeda T; Sugimachi K; Yamashita Y; Ikegami T; Uchiyama H; Yoshizumi T; Soejima Y; Kawanaka H; Mimori K; Watanabe M; Maehara Y
Fukuoka Igaku Zasshi; 2013 Dec; 104(12):549-58. PubMed ID: 24693683
[TBL] [Abstract][Full Text] [Related]
5. Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience.
Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Wang HS; Chen PM
Jpn J Clin Oncol; 2000 Jan; 30(1):12-6. PubMed ID: 10770562
[TBL] [Abstract][Full Text] [Related]
6. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters.
Ohwada S; Ogawa T; Makita F; Tanahashi Y; Ohya T; Tomizawa N; Satoh Y; Kobayashi I; Izumi M; Takeyoshi I; Hamada K; Minaguchi S; Togo Y; Toshihiko T; Koyama T; Kamio M
Oncol Rep; 2006 Apr; 15(4):861-8. PubMed ID: 16525672
[TBL] [Abstract][Full Text] [Related]
8. Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan.
Jpn J Clin Oncol; 1995 Jun; 25(3):91-103. PubMed ID: 7596054
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of colorectal cancer. Results of multivariate analysis of curative resection cases with or without adjuvant chemotherapy.
Takahashi T; Kato T; Kodaira S; Koyama Y; Sakabe T; Tominaga T; Hamano K; Yasutomi M; Ogawa N
Am J Clin Oncol; 1996 Aug; 19(4):408-15. PubMed ID: 8677916
[TBL] [Abstract][Full Text] [Related]
10. [[Cooperative study on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer (II). Cooperative study group on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer supported by the Ministry of Health and Welfare (Kondo's group])].
Imaizumi M; Kondo T; Kamei H; Ichihashi H
Gan To Kagaku Ryoho; 1990 Dec; 17(12):2397-403. PubMed ID: 2124433
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines.
Koda K; Miyazaki M; Sarashina H; Suwa T; Saito N; Suzuki M; Ogawa K; Watanabe S; Kodaira S; Nakazato H
Int J Oncol; 2003 Jul; 23(1):165-72. PubMed ID: 12792790
[TBL] [Abstract][Full Text] [Related]
12. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer.
Iino Y; Yokoe T; Maemura M; Horiguchi J; Takei H; Ohwada S; Morishita Y
Anticancer Res; 1995; 15(6B):2907-11. PubMed ID: 8669887
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of the eligibility of elderly colorectal cancer patients for adjuvant chemotherapy combined with polysaccharide K].
Munemoto Y; Takashima Y; Saito K; Kato S; Kadoya S; Terada T; Amaya S; Ishida M; Iida Y; Mitsui T
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1593-5. PubMed ID: 24393859
[TBL] [Abstract][Full Text] [Related]
14. Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer.
Sakai T; Yamashita Y; Maekawa T; Mikami K; Hoshino S; Shirakusa T
Cancer Biother Radiopharm; 2008 Aug; 23(4):461-7. PubMed ID: 18771350
[TBL] [Abstract][Full Text] [Related]
15. Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2935-8. PubMed ID: 9329568
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Nakazato H; Koike A; Saji S; Ogawa N; Sakamoto J
Lancet; 1994 May; 343(8906):1122-6. PubMed ID: 7910230
[TBL] [Abstract][Full Text] [Related]
17. [Clinical effect of postoperative adjuvant immunochemotherapy with the FT-207 suppository and PSK in colorectal cancer patients. Colorectal Cancer Chemotherapy Group in Hokuriku].
Takashima S; Kinami Y; Miyazaki I
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2229-36. PubMed ID: 3136695
[TBL] [Abstract][Full Text] [Related]
18. Post-chemotherapeutic CEA and CA19-9 are prognostic factors in patients with colorectal liver metastases treated with hepatic resection after oxaliplatin-based chemotherapy.
Sakamoto Y; Miyamoto Y; Beppu T; Nitta H; Imai K; Hayashi H; Baba Y; Yoshida N; Chikamoto A; Baba H
Anticancer Res; 2015 Apr; 35(4):2359-68. PubMed ID: 25862901
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia.
Yi JH; Kim H; Jung M; Shin SJ; Choi JS; Choi GH; Baik SH; Min BS; Kim NK; Ahn JB
Oncology; 2013; 85(5):283-9. PubMed ID: 24217184
[TBL] [Abstract][Full Text] [Related]
20. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK.
Yokoe T; Iino Y; Takei H; Horiguchi J; Koibuchi Y; Maemura M; Ohwada S; Morishita Y
Anticancer Res; 1997; 17(4A):2815-8. PubMed ID: 9252721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
